Vascepa is a prescription medicine that contains the active substance icosapent ethyl and is used to treat high levels of triglycerides in the blood. The medicine is marketed by Amarin Corporation and is approved for use in the United States, Canada, and Europe.

According to the European Medicines Agency (EMA) [2], Vascepa, also known as Vazkepa in Europe, has been approved for use in adults who have high levels of triglycerides in their blood and are at risk of developing cardiovascular disease. The approval was based on the results of a clinical trial that showed that Vascepa reduced the risk of major cardiovascular events in patients with high triglyceride levels.

The EMA also states that Vascepa should be used in combination with a statin or other lipid-lowering therapy, as it has been shown to be more effective when used in combination with these medications [2].

Amarin Corporation has announced plans to maximize the blockbuster potential of Vascepa in Europe [3]. The company plans to expand its commercial operations in Europe and has initiated a cardiovascular outcomes trial to evaluate the long-term effects of Vascepa in patients with elevated triglyceride levels and other cardiovascular risk factors.

In conclusion, Vascepa has been approved in Europe for the treatment of high levels of triglycerides in the blood and is recommended to be used in combination with a statin or other lipid-lowering therapy. Amarin Corporation has plans to expand its commercial operations in Europe and conduct further clinical trials to evaluate the long-term effects of Vascepa in patients with elevated triglyceride levels and other cardiovascular risk factors.

Sources:
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/vazkepa
[3] https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-plans-maximize-blockbuster-potential-vascepar